As of 2023, the re-imbursed pharmaceutical market in Spain for generics stood at a certain value. The forecast from 2024 to 2028 indicates a gradual year-on-year increase: from 24 in 2024, to 24.4 in 2025, gradually reaching 25.1 in 2028. The ongoing yearly variations indicate a consistent upward trend with slight year-on-year growth rates around 1% to 1.4%. Over a 5-year period, the Compound Annual Growth Rate (CAGR) presents a moderate yet steady increase, reflecting the sustained expansion of the generics segment.
Future trends to watch for include the potential impact of policy changes within the Spanish healthcare system, advancements in generic drug technologies, and the evolving competition from patented drugs as they reach the end of their exclusive market period. Monitoring these factors will be essential to understand the dynamics and the sustainability of the growth in this sector.
